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Background: Pulmonary complications often occur in patients with leuke- 
mia and severe aplastic anemia. Particularly in patients having undergone 
bone marrow transplantation, respiratory diseases account for a significant 
number of deaths. In a retrospective study, we evaluated 41 patients with 
leukemia and severe aplastic anemia who were operated on consecutively 
from 1980 to 1995. Methods: Fourteen open lung biopsies, four video- 
assisted lung biopsies, and 24 lung resections were performed in 24 male 
and 17 female patients. Mean age was 32.2 years. Results: Eleven (27%) 
early deaths occurred (30-day mortality): ten in patients after lung biopsy 
(56%) and one after lung resection (4%) (p < 0.001). Perioperative 
morbidity relating to pulmonary disease or operation included 10 (24.4%) 
cases of prolonged (>24 hours) postoperative mechanical ventilation and 
two (4.8%) cases of bleeding or hematoma. In one (2.4%) patient a slowly 
developing, contained bronchial stump insufficiency appeared after lobec- 
tomy, which was successfully operated on 3 weeks later. Conclusion: We 
conclude that resection of localized pulmonary lesions, be it for diagnostic 
or therapeutic (or combined) purposes, can be carried out with low 
morbidity and mortality in patients with leukemia and severe aplastic 
anemia. However, early mortality is high after open or thoracoscopic lung 
biopsies in patients with acute-onset diffuse pulmonary disease, and little 
therapeutic benefit is realized in these cases. (J Thorac Cardiovasc Surg 
1997;113:982-8) 
T he number of patients with acquired forms of immunosuppression has risen continuously over 
the past two decades as a result of modern medical 
therapy of previously intractable diseases, 1 solid 
organ transplantation, and bone marrow transplan- 
tation. In the course of their illness many of these 
patients have pulmonary complications usually 
caused by one of five pathogenetic mechanismsl: (1) 
extension of the underlying disease process to in- 
volve the lungs, (2) opportunistic infection(s), (3) 
pulmonary reaction to therapy (drugs, irradiation, 
bone marrow transplantation), (4) a new, unrelated 
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disease process (i.e., cardiac pulmonary edema or 
emboli), and (5) any combination of the aforemen- 
tioned items. It is often impossible to obtain a 
reliable diagnosis on clinical and radiologic grounds 
alone, and sputum culture is known to be of limited 
value. Invasive diagnostic procedures such as bron- 
choscopy and bronchoalveolar lavage (BAL) are 
advocated to begin effective treatment. However, a 
negative result of BAL does not exclude infection, 
and the need for histologic examination of lung 
tissue or resection of diseased tissue may arise. The 
role of diagnostic and therapeutic surgery in pa- 
tients with leukemia or aplastic anemia also remains 
a subject of controversy. 
The aim of this study was to analyze our series of 
patients to assess mortality and morbidity, diagnos- 
tic and therapeutic benefit, and to attempt to define 
future guidelines for surgery. 
Patients and methods 
The investigated population comprised 41 consecutive 
patients with hematologic diseases and pulmonary corn; 
plications who underwent diagnostic and therapeutic tho- 
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racic operations from January 1980 to December 1995. 
Mean age was 32.2 years (standard eviation [SD] 16.8 
years, ranging from 6 to 69 years). Twenty-four patients 
were male and 17 were female. Thirty-two had leukemia, 
and nine had severe idiopathic aplastic anemia. Before the 
operation, treatment of the hematologic disease had been 
bone marrow transplantation in 18, chemotherapy in 15, 
and antilymphocyte globulin in eight patients (Fig. 1). 
A detailed retrospective analysis of hospital records and 
review of all chest x-ray films, thoracic omputed tomo- 
graphic scans, and histologic sections was performed. The 
patients were treated in the hemato-oncologic isolation 
department under prospectively recorded standardized 
conditions according to defined protocols for hematologic 
malignant diseases or severe idiopathic aplastic ane- 
mia.=' 3
Twenty-three parameters including the following were 
investigated: sex, age, diagnosis and therapy of hemato- 
logic disease, results of preoperative sputum and BAL 
studies, preoperative chest roentgenography and com- 
puted tomographic s anning, histologic and microbiologic 
assessment of lung tissue specimens, type of operation, 
granulocyte and platelet counts, change of medication 
after operation, intraoperative blood toss, administration 
of blood, perioperative (30-day) mortality, postoperative 
morbidity, and certain intervals uch as occurrence of first 
respiratory symptoms until date of operation and occur- 
rence of first radiologic hanges until operation. 
A radiologically diffusepattem was defined as changes on 
chest x-ray films and computed tomographic s ans affect- 
ing all lobes of both lungs. A localized pattern did not 
necessarily indicate existence of just one single lesion. A 
gathering of a few spherical or patchy delineated lesions 
was also classified as localized, so long as the changes did 
not occur in all lobes. 
Results of preoperative sputum and BAL studies were 
classified as corresponding or not corresponding to the 
results from tissue specimens. For instance, if sputum was 
negative for pathogenic bacteria nd both histologic and 
microbiologic lung tissue examinations were also negative, 
the result would be described as corresponding. Sputum 
positive for pathogens but without confirmation in lung 
tissue was classified as not corresponding, aswas negative 
sputum with detection of microbial agents in the tissue 
probe. 
Specific histologic hanges comprised results of sections 
and microbiologic investigations of lung specimens dis- 
closing pneumonitis with a causative bacterial, viral, or 
fungal microorganism, aswell as diagnoses uch as pul- 
monary leukemic infiltration and pulmonary embolism. 
The designation onspecific histology covered noninfec- 
tious inflammatory diseases uch as idiopathic interstitial 
pneumonitis (Table I). We distinguished between specific 
and nonspecific histologic characteristics, because this 
distinction would directly influence effectiveness of man- 
aging the respiratory disease. 
Changes in medication after results had been obtained 
from tissue specimens were divided into the categories no 
change or nondirected change versus directed change. For 
example, new antibiotic treatment in accordance with 
pathogen sensitivity and the ability to stop antibiotic 
treatment were defined as a directed change. In contrast, 
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Fig. 1. The series comprised 41 patients, with a mean age 
of 3.2 years (range 6 to 69 years). Twenty-four patients 
were male (mean age 31.0 years) and 17 were female 
(mean age 33.4 years). CTH, Chemotherapy; ALG, anti- 
lymphocyte globulin; BMT, bone marrow transplant; SAA, 
severe aplastic anemia; AML, acute myelogenous leuke- 
mia; ALL, acute lymphocytic leukemia; CML, chronic 
myelogenous leukemia; CLL, chronic lymphocytic leuke- 
mia. 
empirical change in antibiotic treatment that did not 
correspond to sensitivity testing was classified a nondi- 
rected change. 
Statistical analysis was carried out by one of us (J.D.) 
with SPSS for Windows, version 7.0 (SPSS, Inc., Chicago, 
Ill.). Comparisons of proportions were performed by the 
two-tailed X 2 test or Fisher's exact test, as appropriate. 
Continuous parameters were first tested for normal dis- 
tribution of data by the Shapiro-Wilk test. Depending on 
the results, analysis of variance was used for normally 
distributed ata and the Mann-Whitney test otherwise. 
Effect size was described by odds ratio (OR) and corre- 
sponding 95% confidence intervals (CI). 
Results 
Operations. A total of 42 diagnostic (n = 18) and 
therapeutic (n = 24) lung resections were per- 
formed. Fourteen open lung biopsies were per- 
formed through small anterolateral thoracotomies 
and four video-assisted thoracoscopic (VATS) 
wedge biopsies were done. Four of these patients 
were already receiving mechanical ventilatory sup- 
port before the operation. Therapeutic resections 
comprised 17 lobectomies, one bilobectomy, one 
segmentectomy, and five single or multiple wedge 
resections, one patient having undergone bilateral 
staged wedge resections. 
Histology and preoperative diagnostic proce- 
dures. An overview of the histologic results and 
their relation to radiologic pattern and type of 
operation is presented in Table I. The most frequent 
findings were fungal infections (14/21 or 66.7%) in 
the group with specific histologic findings and idio- 
pathic interstitial pneumonitis (13/21 or 61.9%) in 
those with nonspecific histologic findings. 
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Fig. 2. Interstitial pneumonitis (hematoxylin and eosin stain; original magnification ×115) with fibrosing 
alveolitis. Note widened alveolar septa containing fibrocytes (left arrow) and associated intraalveolar 
hyaline membranes with fibrin exudate and macrophages (center arrow). 
Table I. Relation between histology, radiologic 
pattern, and type of operation (n = 42 interventions) 
Specific No. Nonspecific No. 
Histology 
Fungal infection 14 Interstitial pneumonitis 13 
(nonmicrobial, nonviral) 
Aspergillus 9 
Mucormycosis 1 
No culture available 4 
Abscess (bacterial) 2 Bronchiolitis obliterans 5 
Embolus 2 Scar tissue + bron- 1 
chiolitis obliterans 
(circumscript) 
Leukemic infiltrate 1 Lymphoid interstitial 1 
pneumonitis 
Chlamydia pneumonitis 1 Hyporeactive fibrinous t 
pneumonitis 
RSV pneumonitis 1 
Radiologic pattern 
Localized 18 10 
Diffuse 3 11 
Type of operation 
Resection 17 7 
Biopsy 4 14 
RSV,, Respiratory s ncytial virus. 
Results from preoperative sputum specimens 
were accessible in 27 patients. In cases in which 
microorganisms were responsible for pulmonary dis- 
ease, the microorganisms were correctly detected in 
only 8.3% (1/12) and no fungal infection was diag- 
nosed beforehand by examination of sputum. Secre- 
tion specimens were obtained with a bronchoscope 
and BAL was performed in a total of 28 patients. 
Causative microorganisms were correctly identified 
in only 36% (4/11). Results of the aforementioned 
investigations corresponded to results of tissue anal- 
ysis in 44.5% (12/27) of sputum studies and in 57.1% 
(16/28) of bronchoscopic examinations such that no 
causative microorganisms could be detected in ei- 
ther examination. 
Preoperative fine needle biopsies and transbron- 
chial biopsies were performed in three patients and 
one patient, respectively. The fine needle biopsies 
resulted in nonusable samples in two patients and a 
corresponding result in one patient with interstitial 
pneumonitis. Results of transbronchial biopsy 
showed suspected bronchiolitis obliterans in one 
patient before the operation, which was confirmed 
by VATS biopsy. 
Mortality. Total early postoperative mortality (30- 
day) amounted to 26.8% (Table II). All but two deaths 
were due to respiratory failure caused by the pulmo- 
nary disease; the other two patients died of acute 
leukemic relapse and intracerebral hemorrhage. 
Statistical analysis howed the early mortality rate 
in patients with a diffuse radiologic pattern to be 
significantly higher than that of patients with a 
localized pattern. The same was true of patients 
having lung biopsies and of patients requiring me- 
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Table II. Postoperative mortality and morbidity 
Total Resection Biopsy p Value 
Mortality (30-day) 
Morbidity 
Postop. ventilation >24 hr 
Pneumothorax* 
Bleedingt 
Bronchial stump insufficiency 
Intraop. blood loss (ml):) 
Intraop. blood (units):) 
Blood until second postop, day (units):) 
il/41 (26.8%) 1/23 (4.3%) 10/18 (55.6%) <0.001 
10/42 (23.8%) 1/24 (4.2%) 9/18 (50%) 0.012, 
2/42 (4.8%) 0/24 2/18 (11.1%) 0.201 
2/42 (4.8%) 1/24 (4.2%) 1/18 (5.6%) 0.999 
1/42 (2.4%) 1/24 (4.2%) 0/18 0.999 
298 (SD 316) 425 (SD 327) 92 (SD 169) <0.001 
0.6 (SD 0.8) 1.0 (SD 0.9) 0.2 (SD 0.4) 0.002 
1.8 (S D 1.5) 2.1 (SD t.4) 1.4 (SD 1.6) 0.06"/ 
*Pneumoth0rax requiring secondary drainage. 
?Bleeding requiring intervention rsecondary drainage. 
SData represent mean and standard eviation (SD). 
chanical ventilation before the operation (Table 
tII). 
In patients with leukemia the early mortality was 
31.2% ~(10/32) versus 11.2% (1/9) in patients with 
severe aplastic anemia (p = 0.401; OR 3.64; CI 0.40 
to 33.12). Early mortality in patients after bone 
marrow transplantation was significantly higher 
(44.5%, 8/18) than in patients with aplastic anemia 
who were treated with antilymphocyte s rum (0/8) 
(p = 0.031; OR oo; CI 1.3 to 2). In patients under- 
going biopsies, the mean duration of clinical symp- 
toms such as fever, cough, and dyspnea was 4.3 
weeks (SD 45 weeks) in survivors versus 2.4 weeks 
(SD 1.4 weeks) in nonsurvivors (p = 0.322). Mean 
interval from appearance of radiologic hanges to 
operation was 23 days (SD 40.5 days) in survivors 
versus 7.4 days (SD 8.7 days) in nonsurvivors (p = 
0.528). These intervals, although not statistically 
significant, reflect a more rapid progressio n of re- 
spiratory distress in nonsurvivors. In patients with 
directed change in medication after the operation, 
the early mortality was 15.8% (3/19) as opposed to 
36.4% (8/22) in patients without any (or nondi- 
rected) change in medication (p = 0.173; OR 0.33; 
CI 0.07 to 1.48). 
All late deaths (n = 12) were due to a relapse of 
hematologic disease or complications ofchemother- 
apy and, in patients who had had bone marrow 
transplantation, usually graft-versus-host reactions. 
At end of the study, 18 of the 41 patients (43.9%) 
were long-term survivors; their mean survival time 
amounted to 47.5 months (ranging from 1 to 148 
months). 
Morbidity, One day before the operation the 
platelet count was 99.7 × 103/~1 with 32% (13/41) of 
patients having counts under 40 × 103/bd. However 
56% (23/41) of patients had already received plate- 
Table III. Parameters associated with early 
(30-day) mortality 
No. Deaths OR CI p VaNe 
Radiologic pattern 
Diffuse 
Localized 
Type of operation 
Lung biopsy 
Resection 
Mechanical ventilation* 
Yes 
No 
14 9 22.5 3.7-137.2 0.0002 
27 2 
18 10 27.5 3.0-250.5 0.0003 
23 1 
4 4 ~ 3.0-~ 0 .0~ 
37 7 
OR, Odds ratio; CI, 95% confience interval. 
*Before operation. 
lets at that time. Mean granulocyte count was 4.7 × 
103//xl 1 day before the operation. Seventy-three 
percent (30/41) of patients had counts under 3000/ 
/xl, which reflects ahigh number of patients in whom 
aplasia was the result of chemotherapy or idiopathic 
aplastic anemia. Intraoperative blood loss (Table II) 
was significantly lower in the biopsy group (92 ml) 
than in the resection group (425 ml). However, 
mean preoperative platelet count was also signifi: 
cantly higher for the biopsy group (137.9 × 103//xl; 
SD 99 × 103//M) than for the resection group 
(70.9 × 103txl; SD 85.2 × 103//zl, p = 0.024), possibly 
influencing blood loss also. The amount of blood 
administered during the operation was significantly 
less in the biopsy group (0.2 units) than in the 
resection group (1.0 units); the amount adminis- 
tered after the operation up to the second postop- 
erative day, however, was not significantly higher. 
Further morbidity related to the operation and 
necessitating operative intervention (hematoma, 
bleeding) was seen in two patients (4.8%). None of 
the patients underwent rethoracotomy forpostoper- 
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ative bleeding. Ten patients (24.4%) also needed 
prolonged (>24 hours) postoperative mechanical 
ventilation. All except one of these patients had had 
biopsies. One patient (2.4%) had a slowly develop- 
ing, contained bronchial stump insufficiency after 
right upper lobectomy, which was successfully oper- 
ated on 3 weeks later (see Table II). 
Discussion 
Severe aplastic anemia and leukemia are lethal 
illnesses necessitating the use of extraordinary ther- 
apeutic modalities, and pulmonary complications 
are numerous. Surgeons may be hesitant when 
dealing with these patients. First of all, the poor 
prognosis of the hematologic disease may deter 
them from undertaking a potentially therapeutic 
operation. In addition, the physical condition of the 
patients, involving risk factors such as coagulation 
disorders, thrombocytopenia, and predisposition to 
infectious complications, as well as prolonged post- 
operative intensive care, may give rise to legitimate 
concerns regarding the appropriateness of thoracic 
surgery. The aim of this study was to investigate 
whether the risk of surgery is justified in view of 
early mortality, morbidity, and therapeutic benefit in 
all or certain subgroups of patients with hematologic 
diseases. 
The data presented show that it is important o 
distinguish between biopsies and resections. This 
may seem self-evident at first. However, in contrast 
to what one would expect, larger operations such as 
lobectomies have a significantly lower mortality 
(4.3%) than open and VATS lung biopsies (55.6%). 
This strongly suggests that neither the extent of lung 
tissue resection or the risk of bleeding, infectious 
complications, or other aspects of operative trauma 
are definitive causes of early mortality, but rather 
the degree of respiratory impairment caused by the 
pulmonary disease itself. 
Diffuse disease. The majority of lung biopsies 
were done in patients with radiologically diffuse 
changes, and histologic examination often revealed 
nonspecific inflammatory reactions (see Table I) 
such as idiopathic interstitial pneumonitis. The pa- 
tients already receiving mechanical respiratory sup- 
port before the operation also belonged to this 
category. Clinically manifest interstitial pneumonitis 
(see Fig. 2) is a widely known complication of 
radiotherapy, chemotherapy, and bone marrow 
transplantation,4. 5 which occurs in up to 40% 5 of 
patients and may have a 50% mortality. 1 Pathogen- 
esis is multifactorial, and radiation as well as cyto- 
toxic drugs, viral infections, and other factors such 
as mismatched grafts and cyclosporine A play a role. 
Cytomegalovirus infection is a frequent finding in 
interstitial pneumonitis in some studies. 1 However. 
we could not find a single case of documented 
cytomegalovirus pneumonitis m our histologic sec- 
tions, possibly because the patients who had had 
bone marrow transplantation i this population 
were receiving antiviral medication and cytomega- 
lovirus-negative blood products before the lung 
biopsy. Furthermore. this treatment was usually also 
combined with broad-spectrum empiric antimvcotic. 
antibacterial, and steroid medication. 
The presented results and those of others 6' 7 have 
shown a high early mortality of up to 62% after lung 
biopsies in patients with hematologic disorders, usu- 
ally as a result of respiratory failure. In patients with 
diffuse disease it is not clear that even rapid identi- 
fication of the cause after the beginning of respira- 
tory compromise will lower the mortality. 7' s Some 
authors found patients with open lung biopsies to 
have an even worse outcome than patients without 
lung biopsy, and it has been speculated that this 
outcome might be related to morbidity of the pro- 
cedure itself. 6' 7 However, in our experience surgical 
morbidity and respiratory impairment caused by 
small anterolateral thoracotomies or VATS proce- 
dures are limited. Moreover. we found a slightly 
higher frequency of directed change (21/41; 51%) in 
therapy after biopsy than the 10% to 20% substan- 
tive changes tated by others, v New antibiotic treat- 
ment after detection of a specific microbial organ- 
ism constitutes a directed change in therapy; 
however, the possibility to stop a broad-spectrum 
empirical regimen of antibiotic or tuberculostatic 
medications and to begin high-dose steroids in 
proven noninfectious inflammatory reactions must 
be equally termed a substantial or a directed change 
in therapy. Interpretation is even more complex. 
because no change in therapy does not necessarily 
mean that a biopsy was futile. No change can also 
mean that a biopsy was successful by confirming a
correct treatment begun before the operation. 
Whether "successful" biopsies then can alter the 
clinical course remains to be seen, but after review- 
ing our data we believe that open or VATS biopsies 
in diffuse pulmonary disease can be of value in 
certain instances. Indications must be evaluated in 
each individual case. Although the difference did 
not reach statistical significance, it is important o 
distinguish between patients with acute-onset, dif- 
fuse pulmonary disease with rapidly progressing 
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respiratory distress and those with late-onset disease 
with a slow clinical course. In the latter, lung 
biopsies are often of diagnostic and therapeutic use, 
and the VATS technique with one-lung ventilation 
can be chosen. We found some cases of bronchiolitis 
obliterans and lymphoid interstitial pneumonitis, 
both of which are speculated to be graft-versus-host 
reactions in patients who have had bone marrow 
transplantation,9, 10 as well as one case of respiratory 
syncytial virus pneumonitis. In acute-onset disease 
the interventions are most often in vain, especially 
when broad-spectrum empiric therapy has already 
been administered. In those patients already intu- 
bated and receiving mechanical ventilation the 
VATS approach does not offer much advantage with 
regard to pain management. Also, changing from a 
single-lumen to a double-lumen tube and one-lung 
ventilation with 100% oxygen may jeopardize the 
well-being of patients with severe respiratory insuf- 
ficiency or aggravate preexisting pulmonary hyper- 
tension. Whenever the decision eeds to be made to 
perform a biopsy in patients with acute onset and 
rapid progression of respiratory distress, this should 
be done expeditiously and before empiric medica- 
tion is begun. 
Localized disease. Focal lung lesions after bone 
marrow transplantation have been demonstrated to 
be fungal in up to 78% of patients, u In the pre- 
sented population of patients with leukemia and 
aplastic anemia having undergone resections of ra- 
diologically localized disease, 58% proved to have 
fungal infections, the predominant agent being As- 
pergillus (see Table I). Only one patient had radio- 
logic evidence of cavitary disease. The usual finding 
was a mass or localized infiltrate. Histologically, 
aspergillosis was invasive, which is a known finding 
in patients with neutropenia nd differs from classic 
aspergilloma. 12 Over the past few years several 
positive reports on therapeutic surgery for this indi- 
cation have been published, 1215 and our results 
confirm this. Doubts remain, however, whether sur- 
gical treatment is necessary or whether antimycotic 
treatment alone is sufficient. One argument in favor 
of resection is that mycotic infections in patients 
with neutropenia usually show a tendency to grow 
under full antimycotic treatment, because these 
medicaments are not effective enough owing to 
insufficient cellular defense and limited diffusion of 
drugs in necrotic tissue. If aplasia is severe and 
long-lasting, as in the case of severe idiopathic 
aplastic anemia, conservative treatment may have 
unsatisfactory esults with patients dying of dissem- 
ination or complications of invasion (i.e., hemor- 
rhage). If aplasia is transitory, as in the case of 
patients with leukemia after a chemotherapeutic 
cycle, it can be argued that a fungal infection 
occurring at the end of an aplastic episode may heal 
with medical therapy alone inasmuch as the cellular 
reaction will continuously increase. However, the 
low mortality and morbidity of resections observed 
in this study suggest that the risk of waiting is higher 
than the risk of operating. In our patient population 
no recurrence of mycotic disease was observed in 
the lung or elsewhere after resections, which were 
usually therapeutic and complete in radiologically 
localized disease. Another important argument in 
favor of surgery is that preoperative diagnosis is 
often lacking or uncertain. In our population my- 
cotic infection was confirmed by bronchoscopic n- 
vestigations in only 25% (2/8) of patients before the 
operation. Sputum was negative for pathogens in all 
patients with fungal infection. Furthermore, we 
deem percutaneous needle aspirations in patients 
with aplastic anemia to be dangerous, because we 
have seen catastrophic hemorrhage with lethal out- 
come. 
Platelets and if necessary fresh frozen plasma are 
administered before and during the operation, 
with the aim of raising platelet counts to 40,000/ 
txl. Mean intraoperative blood loss is low for 
resections, and the amount of blood administered 
during the first 2 days after the operation is not 
significantly higher in patients having resections 
than in those having biopsies. This suggests that 
intraoperative hemorrhage or continuous postop- 
erative oozing is rare. Hence, for diagnostic and 
therapeutic reasons, we advocate that resection of 
single or few ipsilateral delineated lesions devel- 
oping or persisting despite antibiotic and antimy- 
cotic therapy be carried out as early as possible. 
Rarely, we have even done this in patients with 
hematologic disorders who had no clinical symp- 
toms. In contrast, if there are a multitude of 
bilateral esions and the patient's condition dete- 
riorates rapidly, operation is not indicated and an 
attempt at control with high-dose antifungal 
agents should be undertaken. In such cases my- 
cotic infections will often spread systemically and 
no effective therapy remains. However, one pa- 
tient in this series with a good clinical course and 
general condition was able to undergo staged 
excisions bilaterally, with the first resection yield- 
ing necrotic lung tissue invaded byAspergillus and 
the subsequent contralateral resections yielding 
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nonspecific scar tissue, probably resulting from 
resolved mycotic infiltrates. 
Conclusions 
In patients with hematologic disorders who have 
pulmonary complications, early mortality and mor- 
bidity of lung resections and biopsies are usually due 
to the pulmonary disease itself, not to the extent or 
complications of the operation. 
Resection of localized pulmonary disease in pa- 
tients with leukemia and aplastic anemia is feasible 
with acceptably low mortality and morbidity, and is 
often carried out for therapeutic as well as diagnos- 
tic reasons. Excessive perioperative blood loss 
caused by the aplastic state seldom occurs so long as 
platelets are administered. Lung tissue and bron- 
chial stumps usually heal without difficulty. 
Early mortality for lung biopsies in acute-onset 
diffuse pulmonary disease is high, and therapeutic 
benefit remains questionable in these patients, es- 
pecially when broad empiric therapy has already 
been administered. In late-onset diffuse disease, 
patients may profit by lung biopsies, as directed 
change in therapy and positive effect of treatment 
are observed more often. 
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